Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MART-1 Reactive PBL with or without Aldesleukin in Metastatic Melanoma
NCT01495572Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2011
- Primary completion
- Feb 2014
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes in melanoma, sponsored by National Cancer Institute. Started Dec 2011; status: terminated.
02
Drugs
autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01495572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01495572.